MYND Life Sciences Inc. (MYNDF)
USD 0.06
(0.0%)
USD 0.06
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -1.82 Million CAD | 31.28% |
| 2022 | -3.72 Million CAD | 13.17% |
| 2021 | -4.29 Million CAD | -7500.29% |
| 2020 | -56.46 Thousand CAD | -2127.46% |
| 2019 | -2535.00 CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -341.77 Thousand CAD | -54.49% |
| 2024 Q2 | -221.23 Thousand CAD | 33.85% |
| 2024 Q1 | -334.43 Thousand CAD | 13.93% |
| 2023 Q4 | -388.54 Thousand CAD | -23.57% |
| 2023 FY | -2.56 Million CAD | 31.28% |
| 2023 Q3 | -314.42 Thousand CAD | 28.02% |
| 2023 Q2 | -436.83 Thousand CAD | 32.34% |
| 2023 Q1 | -645.59 Thousand CAD | -126937.96% |
| 2022 Q2 | -717.18 Thousand CAD | 37.87% |
| 2022 Q1 | -1.15 Million CAD | 27.44% |
| 2022 FY | -3.72 Million CAD | 13.17% |
| 2022 Q4 | -508.19 CAD | 99.93% |
| 2022 Q3 | -682.74 Thousand CAD | 4.8% |
| 2021 Q2 | -762.42 Thousand CAD | 35.39% |
| 2021 Q4 | -1.59 Million CAD | -86.43% |
| 2021 Q3 | -853.33 Thousand CAD | -11.92% |
| 2021 FY | -4.29 Million CAD | -7500.29% |
| 2021 Q1 | -1.18 Million CAD | 0.0% |
| 2020 FY | -56.46 Thousand CAD | -2127.46% |
| 2019 FY | -2535.00 CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 97.452% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 137.209% |
| SQZ Biotechnologies Company | -75.82 Million USD | 97.588% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 89.753% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 102.234% |
| Mesoblast Limited | -84.14 Million USD | 97.827% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -19.056% |
| Genus plc | 6.4 Million USD | 128.574% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 118.771% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -96.35% |
| Marizyme, Inc. | -34.08 Million USD | 94.635% |
| ContraFect Corporation | -56.88 Million USD | 96.785% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 78.099% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 59.849% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -30.44% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 35.844% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 33.52% |
| MultiCell Technologies, Inc. | -722.81 USD | -252907.429% |
| Accustem Sciences Inc. | -3.74 Million USD | 51.186% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 96.9% |
| EV Biologics, Inc. | -483.06 Thousand USD | -278.577% |
| Q BioMed Inc. | -3.44 Million USD | 46.925% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 151.66% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -369.431% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 30.4% |
| Biomind Labs Inc. | -1 Million USD | -81.137% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | -4.87 Million USD | 62.522% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 72.492% |
| Skye Bioscience, Inc. | -13.67 Million USD | 86.624% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 7.939% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -6005.646% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 63.747% |
| IMV Inc. | -38.67 Million USD | 95.271% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 88.476% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 5.373% |
| GB Sciences, Inc. | -1.42 Million USD | -28.74% |
| Alpha Cognition Inc. | -9.7 Million USD | 81.158% |
| HST Global, Inc. | -140.9 Thousand USD | -1197.851% |
| CSL Limited | 3.7 Billion USD | 100.049% |
| Halberd Corporation | -75.05 Thousand USD | -2336.726% |
| Enzolytics Inc. | -2.14 Million USD | 14.894% |
| Resverlogix Corp. | -12.74 Million USD | 85.656% |
| Affymax, Inc. | -15.04 Million USD | 87.846% |
| SYBLEU INC | -149.18 Thousand USD | -1125.877% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 42.279% |
| argenx SE | -425.04 Million USD | 99.57% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 96.705% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -75.169% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -15.792% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 46.292% |
| AVAX Technologies, Inc. | 6.69 Million USD | 127.324% |
| Zenith Capital Corp. | -8.94 Million USD | 79.551% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.56% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -10397.463% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 25.518% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -966.275% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 96.673% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 36.966% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -85.84% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 1.91% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -45.602% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 8.779% |
| BioStem Technologies, Inc. | -7.77 Million USD | 76.491% |
| ONE Bio Corp. | 13.68 Million USD | 113.367% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -907.666% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -36.942% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -62.57% |
| Agentix Corp. | -1.37 Million USD | -33.315% |
| LadRx Corporation | -3.82 Million USD | 52.172% |
| Cell Source, Inc. | -4.32 Million USD | 57.72% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -340.158% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -166.215% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -166.215% |
| NovAccess Global Inc. | -2.46 Million USD | 25.864% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 37.359% |
| Itoco Inc. | -919.14 Thousand USD | -98.965% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 56.853% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -63.428% |
| Kadimastem Ltd | -3.04 Million USD | 39.848% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -598.732% |
| CytoDyn Inc. | -18.05 Million USD | 89.873% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -7165.646% |
| Mobile Lads Corp. | -554.55 Thousand USD | -229.774% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -730.961% |
| Qrons Inc. | -643.67 Thousand USD | -184.112% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -223.834% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.22 Million USD | 17.988% |
| Rebus Holdings, Inc. | -664 Thousand USD | -175.416% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -0.685% |
| International Stem Cell Corporation | -663 Thousand USD | -175.832% |
| Bioxytran, Inc. | -3.82 Million USD | 52.128% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -3374.094% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -8890.969% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 94.957% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -13.026% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -148.529% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 41.216% |
| Neutra Corp. | -229.48 Thousand USD | -696.895% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 89.573% |
| PureTech Health plc | -146.19 Million USD | 98.749% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 91.491% |
| IXICO plc | -1.43 Million USD | -27.263% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 80.732% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 98.499% |
| CSL Limited | 3.81 Billion USD | 100.048% |
| Cellectis S.A. | -108.85 Million USD | 98.32% |